1. Home
  2. RDHL vs SLXN Comparison

RDHL vs SLXN Comparison

Compare RDHL & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDHL
  • SLXN
  • Stock Information
  • Founded
  • RDHL 2009
  • SLXN 2008
  • Country
  • RDHL Israel
  • SLXN Israel
  • Employees
  • RDHL N/A
  • SLXN N/A
  • Industry
  • RDHL Biotechnology: Pharmaceutical Preparations
  • SLXN
  • Sector
  • RDHL Health Care
  • SLXN
  • Exchange
  • RDHL Nasdaq
  • SLXN NYSE
  • Market Cap
  • RDHL 8.2M
  • SLXN 5.0M
  • IPO Year
  • RDHL N/A
  • SLXN N/A
  • Fundamental
  • Price
  • RDHL $5.85
  • SLXN $1.26
  • Analyst Decision
  • RDHL
  • SLXN Strong Buy
  • Analyst Count
  • RDHL 0
  • SLXN 1
  • Target Price
  • RDHL N/A
  • SLXN $9.00
  • AVG Volume (30 Days)
  • RDHL 11.1K
  • SLXN 32.1M
  • Earning Date
  • RDHL 04-07-2025
  • SLXN 02-21-2025
  • Dividend Yield
  • RDHL N/A
  • SLXN N/A
  • EPS Growth
  • RDHL N/A
  • SLXN N/A
  • EPS
  • RDHL N/A
  • SLXN N/A
  • Revenue
  • RDHL $3,707,000.00
  • SLXN N/A
  • Revenue This Year
  • RDHL $224.90
  • SLXN N/A
  • Revenue Next Year
  • RDHL $82.69
  • SLXN N/A
  • P/E Ratio
  • RDHL N/A
  • SLXN N/A
  • Revenue Growth
  • RDHL N/A
  • SLXN N/A
  • 52 Week Low
  • RDHL $5.41
  • SLXN $0.21
  • 52 Week High
  • RDHL $20.28
  • SLXN $13.56
  • Technical
  • Relative Strength Index (RSI)
  • RDHL 40.41
  • SLXN N/A
  • Support Level
  • RDHL $5.80
  • SLXN N/A
  • Resistance Level
  • RDHL $6.26
  • SLXN N/A
  • Average True Range (ATR)
  • RDHL 0.31
  • SLXN 0.00
  • MACD
  • RDHL 0.01
  • SLXN 0.00
  • Stochastic Oscillator
  • RDHL 19.33
  • SLXN 0.00

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.

About SLXN BIOMOTION SCIENCES

Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.

Share on Social Networks: